中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

714 records (took 0.016 seconds)

    Anticancer therapy
    581.
    发明授权
    Anticancer therapy 有权

    公开(公告)号：US10172967B2

    公开(公告)日：2019-01-08

    申请号：US15427355

    申请日：2017-02-08

    Applicant: STC.UNM

    Inventor： Jeffrey P. Norenberg

    IPC: A61K51/00 ,  A61K36/14 ,  A61K51/08 ,  A61K31/7068 ,  A61K38/31 ,  A61K45/06

    Abstract: A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

    Defrosting Infrared Windows Using Transparent Metallic Nanostructures
    583.
    发明申请
    Defrosting Infrared Windows Using Transparent Metallic Nanostructures 审中-公开

    公开(公告)号：US20180359815A1

    公开(公告)日：2018-12-13

    申请号：US15736534

    申请日：2016-06-15

    Applicant: STC.UNM

    Inventor： Sang Eon Han

    IPC: H05B3/84

    CPC classification number: H05B3/84 ,  B82Y30/00 ,  G02B1/18 ,  H05B2214/04

    Abstract: An optoelectronic device having a self-defrosting/de-icing window configured to operate at an electromagnetic radiation frequency having metals that are optically transparent as a result of the wires having an effective plasma frequency that is equal to or lower than the electromagnetic frequency at which the device operates. The effective plasma frequency of the wire is lowered by configuring the path of the wire between the terminal ends to be meandering, serpentine, U-shaped and in other non-linear configurations. The metal wires are resistively heated.

    STEP-derived peptide for brain injury treatment
    584.
    发明授权
    STEP-derived peptide for brain injury treatment 有权

    公开(公告)号：US10087429B2

    公开(公告)日：2018-10-02

    申请号：US14721024

    申请日：2015-05-26

    Applicant: Surojit Paul

    Inventor： Surojit Paul

    IPC: C07K14/47 ,  C07K19/00 ,  A61K38/17 ,  A61P25/00 ,  C12N9/16 ,  A61K38/46 ,  A61K38/00

    Abstract: A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). The peptide sequence has been modified so as to be able to ameliorate and treat brain injury resulting from excessive glutamate release and/or oxidative stress. Examples of the types of brain injury which the presently disclosed peptide sequence is useful for treating includes acute brain injury resulting from stroke or traumatic brain injury and chronic disorders such as Huntington's chorea and schizophrenia. Furthermore, the presently described peptide sequence may further be useful in the treatment and amelioration of disorders associated with fear memory such as post-traumatic stress disorder.

    Infusion device
    585.
    发明授权
    Infusion device 有权

    公开(公告)号：US10086132B2

    公开(公告)日：2018-10-02

    申请号：US15330023

    申请日：2016-07-26

    Applicant: STC.UNM

    Inventor： Mark Hauswald

    IPC: A61M5/315 ,  A61M5/145 ,  A61M5/14 ,  A61M5/142 ,  A61M5/168

    Abstract: A mechanical infusion pump device for injecting medication into a patient's IV, includes an IV reservoir and a syringe communicated to the IV reservoir and having a syringe plunger connected to a filling plunger that is moved with the syringe plunger in a first syringe-filling direction to fill the syringe with fluid medication. Biasing weight(s) is/are provided on the filling plunger for exerting bias or force from gravity on the filling plunger and the syringe plunger in a second syringe-discharging direction to dispense medication from the syringe into the patient's IV when the filling plunger is released. Only a calibrated amount of medicine can be discharged to the patent's IV over time as determined by calibration of the biasing weights and the metering element located between the syringe and the patient's IV for a given viscosity of the medication.

    Fractional Anisotropy in MRI as an Indicator of Reversible Pathology
    586.
    发明申请
    Fractional Anisotropy in MRI as an Indicator of Reversible Pathology 审中-公开

    公开(公告)号：US20180249926A1

    公开(公告)日：2018-09-06

    申请号：US15756221

    申请日：2016-08-31

    Applicant: STC.UNM

    Inventor： Shihoko Kimura-Ohba ,  Laurel Sillerud

    IPC: A61B5/055 ,  A61B5/00

    Abstract: The present invention concerns a method for determining whether brain regions of interest having reversible or irreversible pathology. The method includes acquiring over a predetermined period of time a plurality of magnetic resonance imaging (MRI) images for each brain region of interest; analyzing the MRI images to obtain quantitative measurements of the fractional anisotropy (FA) for each brain region of interest and determining that brain regions of interest have reversible pathology when the measured FA increases and then decreases over the predetermined period of time.

    Detection of bioagents using a shear horizontal surface acoustic wave biosensor
    588.
    发明授权
    Detection of bioagents using a shear horizontal surface acoustic wave biosensor 有权

    公开(公告)号：US10031135B2

    公开(公告)日：2018-07-24

    申请号：US14172429

    申请日：2014-02-04

    Applicant: STC.UNM ,  SANDIA CORPORATION

    Inventor： Richard S. Larson ,  Brian Hjelle ,  Pam R. Hall ,  David C. Brown ,  Marco Bisoffi ,  Susan M. Brozik ,  Darren W. Branch ,  Thayne L. Edwards ,  David Wheeler

    IPC: G01N33/543 ,  C12Q1/6825

    Abstract: Viruses and other bioagents are of high medical and biodefense concern and their detection at concentrations well below the threshold necessary to cause health hazards continues to be a challenge with respect to sensitivity, specificity, and selectivity. Ideally, assays for accurate and real time detection of viral agents and other bioagents would not necessitate any pre-processing of the analyte, which would make them applicable for example to bodily fluids (blood, sputum) and man-made as well as naturally occurring bodies of water (pools, rivers). We describe herein a robust biosensor that combines the sensitivity of surface acoustic waves (SAW) generated at a frequency of 325 MHz with the specificity provided by antibodies and other ligands for the detection of viral agents. In preferred embodiments, a lithium tantalate based SAW transducer with silicon dioxide waveguide sensor platform featuring three test and one reference delay lines was used to adsorb antibodies directed against Coxsackie virus B4 or the negative-stranded category A bioagent Sin Nombre virus (SNV), a member of the genus Hantavirus, family Bunyaviridae, negative-stranded RNA viruses. Rapid detection (within seconds) of increasing concentrations of viral particles was linear over a range of order of magnitude for both viruses, although the sensor was approximately 50×104-fold more sensitive for the detection of SNV. For both pathogens, the sensor's selectivity for its target was not compromised by the presence of confounding Herpes Simplex virus type 1. The biosensor was able to detect SNV at doses lower than the load of virus typically found in a human patient suffering from hantavirus cardiopulmonary syndrome (HCPS). Further, in a proof-of-principle real world application, the SAW biosensor was capable of selectively detecting SNV agents in complex solutions, such as naturally occurring bodies of water (river, sewage effluent) without analyte pre-processing.

Patent Agency Ranking